Positron Corporation Acquires Exclusive License to Coronary Disease Reversal and Prevention Practice Management Program From the University of Texas
Positron Corporation (OTC: POSC) (the “Company”) announced today that it has acquired an exclusive license to a coronary disease reversal and prevention practice management program created by K. Lance Gould, M.D. and the University of Texas Health Science Center at Houston.
“We are grateful to the University of Texas Health Science Center at Houston and Dr. Gould for selecting Positron Corporation as the exclusive licensee of their heart disease management product”, stated Joe Oliverio, President of Positron. Oliverio also stated, “the market is void of such a product and will position Positron to be able to offer a total cardiac solution to customers reaching well beyond the sale to physicians.”
“The Weatherhead P.E.T. Center of the University of Texas Health Science Center at Houston is unique for having the most advanced myocardial perfusion imaging in the world using positron emission tomography (P.E.T.) integrated with intense lifestyle and pharmacologic treatment proven to reduce invasive procedures and coronary events compared to conventional cardiovascular practices”, stated K. Lance Gould, M.D., holder of the Martin Bucksbaum Distinguished University Chair, professor of Cardiovascular Medicine and executive director of the Weatherhead P.E.T. Center for Preventing and Reversing Atherosclerosis, University of Texas Medical School at Houston.
Dr. Gould went on to also state, “This first program for the optimal one-stop combination of diagnostic assessment, vigorous pharmacologic and lifestyle management is PET technology driven but incorporates the humanity and knowledge of the best preventive and clinical medicine. It identifies the earliest stages of coronary disease and before symptoms develop. It also determines when invasive procedures are unnecessary or needed for the most advanced complex coronary heart disease.”
“Positron Corporation has recognized the power of this approach for improving cardiovascular care. The University of Texas Health Science Center at Houston- Positron agreement highlights the commitment of the University and Positron for translating the highest quality cardiovascular medicine and research of a renowned academic center into widespread application of community practice.”
About Positron Corporation
Positron Corporation is a growing healthcare company offering cardiac molecular imaging solutions that will transform the delivery of healthcare through radiopharmaceutical development, advancing imaging technology and by introducing unique disease management applications into the market. Positron Corporation designs, manufactures and sells SPECT, PET and automated dose delivery devices in to the Nuclear Medicine market. Additional information may be found at http://www.positron.com/.
This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Positron Corporation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company’s research and development efforts, the availability of adequate financing and other uncertainties described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
For any additional information contact Positron’s President, Joe Oliverio at (281) 492-7100